Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Plasma Viral Load of 200 Copies/mL is a Suitable Threshold to Define Viral Suppression and HIV Drug Resistance Testing in Low- and Middle-Income Countries: Evidence From a Facility-Based Study in Cameroon.
J Int Assoc Provid AIDS Care
December 2024
Chantal BIYA International Reference Centre for Research on HIV/AIDS Prevention and Management, Yaoundé, Cameroon.
Introduction: In low-and-middle-income-countries (LMIC), viral suppression is defined as plasma viral load (PVL) below 1000 copies/mL (low-level viremia [LLV]) and threshold for HIV drug resistance (HIVDR) testing. However, there is evidence that drug resistance mutations (DRMs) may emerge at LLV, thus compromising antiretroviral treatment (ART) response We evaluated sequencing success rates (SSR) at LLV, described HIVDR profiles and adequacy with potential efficacy of tenofovir-lamivudine-dolutegravir (TLD).
Methods: A cross-sectional study was conducted among individuals with LLV at the Chantal BIYA International Reference Centre, Yaoundé, Cameroon from January 2020 through August 2021.
Outcomes of HIV-infected children on antiretroviral therapy for at least 10 years at the Essos Hospital Centre, Cameroon: contributing to the elimination of paediatric AIDS in tropical settings.
J Trop Pediatr
December 2024
African Population and Health Research Centre, Dakar, Dakar 12500, Senegal.
Evidence on long-term outcomes of children receiving antiretroviral therapy (ART) in low- and middle-income countries (LMICs) is of utmost importance to optimize current and future therapeutic strategies for HIV. We sought to ascertain the long-term responses among ART-experienced children and their potential implications. A retrospective, observational, facility-based cohort study was conducted among 136 ART-experienced children monitored for 10 years (2007-2017) at the Essos Hospital Centre in Yaoundé, Cameroon.
View Article and Find Full Text PDFRole of Dolutegravir/Lamivudine in the Management of Pregnant People Living with HIV-1: A Narrative Review.
Infect Dis Ther
December 2024
ViiV Healthcare, 980 Great West Road, Brentford, Middlesex, TW8 9GS, UK.
Article Synopsis
- Lowering viral load during pregnancy is crucial to reduce the risk of HIV-1 vertical transmission, and minimizing drug exposure to the fetus is a key principle.
- While Dolutegravir/lamivudine (DTG/3TC) shows high effectiveness and safety in non-pregnant individuals, its initial use in pregnant HIV-1 patients is not recommended due to limited data.
- Recent studies suggest that DTG/3TC may be effective and safe for pregnant individuals, showing high rates of viral suppression and no increased risk of neural tube defects, making it a potentially preferable option to more complex regimens.
The impact of adherence counseling incorporating a point of care urine tenofovir assay on virologic suppression among individuals failing tenofovir-lamivudine-dolutegravir: A pre-post intervention study.
Int J Infect Dis
February 2025
Centers for Disease Control and Prevention, Division of Global HIV and Tuberculosis, Atlanta, Georgia, USA.
Objectives: To examine if point-of-care (POC) urine tenofovir testing-informed counseling could be used to improve virologic suppression (VS) among participants with virologic failure (VF) after ≥1 prior round of enhanced adherence counseling (EAC).
Methods: Participants were enrolled from 42 clinics across Namibia. At each monthly medication pick-up, participants completed the POC urine test and received EAC informed by this testing (EAC+).
Efficacy and Safety of DRG/3TC for Prophylaxis of HIV Perinatal Transmission: A Pilot Study (PREGNANCY).
Open Forum Infect Dis
December 2024
Centro Especializado em Diagnóstico, Assistência e Pesquisa, Salvador, Bahia, Brazil.
Background: The prevention of perinatal human immunodeficiency virus (HIV) transmission depends on the safe and effective use of antiretroviral therapy (ART). Simplifying treatment reduces drug exposure for both mother and child. We evaluated the safety and efficacy of dolutegravir (DTG) plus lamivudine (3TC) for antiretroviral-naive pregnant women with HIV.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!